Drug Profile
Research programme: anticancer therapeutics - BioMed X/ Merck
Latest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator BioMed X; Merck Serono
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Apr 2023 BioMed X and Merck extend agreement in the research project in enhancing the immunogenicity of tumors in Cancer
- 01 Feb 2022 BioMed X and Merck extend agreement in the research project RNA splicing in Cancer
- 21 May 2021 BioMed X and Merck extend agreement to co-develop candidates for Cancer and Autoimmune disorders